Reports world wide Bipolar Disorder Disease | Page 2

EXECUTIVE SUMMARY
SOURCES AND METHODOLOGY
FORECAST.
CONTINUED……………………………
LIST OF FIGURES
Figure 1: Idiopathic pulmonary fibrosis – current and future market dynamics analysis
Figure 35: Datamonitor Healthcare’s drug assessment summary of pamrevlumab for idiopathic
pulmonary fibrosis
Figure 3: Idiopathic pulmonary fibrosis drug sales across the US, Japan, and five major EU markets,
by country, 2016–25
Figure 4: Total sales categorized by severity across the US, Japan, and five major EU markets, 2016–
Figure 5: Patient-based forecast methodology for idiopathic pulmonary fibrosis
Figure 6: Price sources and calculations, by country
Figure 7: Esbriet for idiopathic pulmonary fibrosis – SWOT analysis
Figure 8: Datamonitor Healthcare’s drug assessment summary of Esbriet for idiopathic pulmonary
fibrosis.
CONTINUED……………………………
LIST OF TABLES
Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare’s idiopathic
pulmonary fibrosis patientbased forecast
Table 2: Exchange rates used for calculating prices
Table 3: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 4: Esbriet drug profile
Table 5: Esbriet Phase III data in idiopathic pulmonary fibrosis
Table 6: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU
markets, by country ($m), 2016–25
Table 7: Ofev drug profile
Table 8: Ofev pivotal trial data in idiopathic pulmonary fibrosis
Table 9: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets,
by country ($m), 2016–25
Table 10: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 11: Subtypes of idiopathic interstitial pneumonias
Table 12: Datamonitor Healthcare’s definition of idiopathic pulmonary fibrosis severity
Table 13: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain
undiagnosed across the US, Japan, and five major EU markets
Table 14: Approved treatments available for idiopathic pulmonary fibrosis across the US, Japan, and
five major EU markets
Table 15: Off-label therapies used in the treatment of idiopathic pulmonary fibrosis across the US,
Japan, and five major EU markets
Table 16: Non-pharmacological therapies used in the treatment of idiopathic pulmonary fibrosis across
the US, Japan, and five major EU markets
Table 17: Pharmacological treatment regimens used in mild idiopathic pulmonary fibrosis patients
across the US, Japan, and five major EU markets, by country.
CONTINUED……………………………
Ask to Expertise @
https://www.reportsworldwide.com/enquiry?report_id=42616
About US:
Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of
market research reports provides in depth coverage of 12 top industry verticals worldwide.